Pragma Bio Stock

Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune diseases.

Sign up today and learn more about Pragma Bio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Pragma Bio Stock

Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

Funding History

May 2018$15K
November 2020$4.5M
March 2023$10.0M

Management

Co-Founder & CEO

Kareem Barghouti

Co-Founder

Ayin Vala

Co-Founder & CSO

Kovi Bessoff

CTO, Co-Founder

Peter McCaffrey

Angel Investor

Samuel Lee

Investor

Todd Meyerrose

Angel Investor

Sameer Khandelwal

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo